Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS-Reference-Cited by-同舟云学术

Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS

Published:2021-11 Issue: Volume:110 Page:106713
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Huselton Eric^ORCID,Rettig Michael P.^ORCID,Campbell Kirsten,Cashen Amanda F.,DiPersio John F.,Gao Feng,Jacoby Meagan A.,Pusic Iskra,Romee Rizwan,Schroeder Mark A.,Uy Geoffrey L.^ORCID,Marcus Stephen,Westervelt Peter

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference59 articles.

1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol.,2009

2. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes;Silverman;Cancer,2011

3. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes;Zeidan;Curr. Opin. Hematol.,2014

4. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis;Cojoc;Onco. Ther.,2013

5. Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells;Sahin;Cell Adh. Migr.,2012

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple functions of HMGB1 in cancer;Frontiers in Oncology;2024-04-25

2. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes;Cancer Treatment Reviews;2024-02

3. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

4. Cancer Stem Cells as a Therapeutic Target: Current Clinical Development and Future Prospective;Stem Cells;2023-12-14

5. Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial;Open Forum Infectious Diseases;2023-10-27